SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant downward pressure after reporting disappointing forward guidance and citing ongoing challenges in the Chinese market, prompting a series of analyst downgrades. Community sentiment is deeply polarized, with many investors debating whether the stock has hit a generational bottom or is caught in a long-term value trap as the brand struggles to maintain its competitive relevance against newer rivals.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is seeing heightened attention following a fiscal third-quarter earnings beat, though investor sentiment remains divided between optimism over potential cannabis policy shifts and concerns regarding the company's persistent cash burn and the performance of its beverage segment. The community is actively debating the company's long-term turnaround strategy, the impact of anticipated U.S. federal regulatory changes, and the leadership of CEO Irwin Simon.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and intense debate among investors as they grapple with a downward trend, leading many to monitor short interest data and potential technical indicators like a short squeeze. Despite current macro-economic pressures and geopolitical concerns weighing on the stock, the community remains polarized between those viewing current levels as a bargain-buy accumulation opportunity and those concerned about the company's long-term path to profitability and lack of clear communication.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is currently experiencing high volatility driven by escalating geopolitical tensions in the Middle East and concerns over oil supply disruptions in the Strait of Hormuz. The community is actively debating the stock's long-term potential amid a complex energy landscape, with sentiment split between those capitalizing on the sector's relative strength and traders attempting to navigate the risks of a potentially protracted conflict.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending following the announcement of a massive multi-year AI infrastructure contract, fueling intense community speculation about its low-float potential to trigger a significant short squeeze. Investors are actively debating the company's valuation shift and potential price volatility, with many comparing the stock to historical high-momentum market movers.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant downward pressure as investors weigh weak earnings and revenue misses against the company's aggressive but costly international expansion. Market sentiment is sharply divided, with bearish traders highlighting high debt levels and persistent housing sector headwinds, while bullish investors are betting on a potential short squeeze fueled by high short interest and speculative hopes for future tariff relief.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor ongoing project developments, including the upcoming pilot plant operations and the status of the Definitive Feasibility Study. Market participants are actively debating the stock's valuation relative to its rare earth assets while navigating volatility driven by broader sector trends and geopolitical developments.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is experiencing significant volatility driven by conflicting headlines regarding the U.S.-Iran conflict, with investors closely monitoring shifting comments on ceasefires and potential military escalations. The community is actively debating whether current market rallies represent a genuine de-escalation of tensions or a tactical trap fueled by speculative trading and political uncertainty.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing extreme volatility as markets react to contradictory reports regarding a potential de-escalation of the conflict in Iran. While community sentiment remains polarized, traders are actively debating whether the rally is a genuine pivot or a bull trap driven by erratic headlines, quarter-end window dressing, and uncertainty surrounding an upcoming national address.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is generating significant buzz among retail traders, largely due to its 10% direct exposure to SpaceX and the broader momentum in the space exploration sector. While some community members are optimistic about its potential for growth, others are debating its transparency, low AUM, and how it compares to established, higher-volatility space plays.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sunshine Biopharma (SBFM) rose 11% on Thursday morning after the company announced that its Canadian unit, Nora Pharma, launched a generic version of Bristol-Myers Squibb’s Pravachol.The drug, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/10/20251016_SBFM_Press-Release_Launches-Pravastatin.pdf">called</a> Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.Nora Pharma’s Pravastatin is available in strengths of 10 mg, 20 mg, and 40 mg, and comes in bottles of 100 tablets.Sunshine Biopharma said that the Canadian market of cholesterol-lowering drugs is estimated to reach $582 million by the end of 2025 and $1.07 billion by 2033.Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada, and more than 12 additional drugs are scheduled to be launched in 2026. The company is also seeking to develop drug candidates in the treatment of liver cancer and coronavirus infections.On Stocktwits, retail sentiment around SBFM stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_10_55_53_AM_png_97567a6c3b.webp" alt="SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company has a bright future.<stembedurl>https://stocktwits.com/Knowledgeworthmore/message/632572691</stembedurl>Another said that they intend to hold the stock long term.<stembedurl>https://stocktwits.com/BanditKnight47/message/632549060</stembedurl>In July, Sunshine Bioopharma <a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-soars-after-launch-of-first-biosimilar-in-10-b-canadian-market-retail-bulls-charge-in/chFjax5Rchk">introduced</a> its first biosimilar drug, Niopeg, to the Canadian market, to treat the risk of infection in cancer patients undergoing chemotherapy. In June, a generic version of Neurontin, Gabapentin, was launched for treating neuropathic pain and epilepsy.SBFM stock is down by 29% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-draws-investor-interest-as-european-regulator-reportedly-terms-door-safety-a-priority/ch6p3LDR3nA">Tesla Stock Draws Investor Interest As European Regulator Reportedly Terms Door Safety A Priority</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.

Equity

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.


Retail chatter around Sunshine Biopharma surged late Wednesday after the company introduced Niopeg, its first biosimilar drug, into the Canadian market,&nbsp;sending its stock soaring by nearly 14% — its best session in over seven months.The treatment, developed by its subsidiary Nora Pharma, is a pegfilgrastim biosimilar to Neulasta, which is commonly used to reduce the risk of infection in cancer patients undergoing chemotherapy.Niopeg is supplied in a 6mg/0.6mL prefilled syringe and is designed for patients with non-myeloid cancers.&nbsp;The company noted that global demand for Neulasta and similar drugs was worth approximately $4.5 billion last year, with expectations that it could rise to $9.2 billion by 2033, driven by increasing cancer cases and wider chemotherapy use.Canada, although a smaller part of the global market, still plays a disproportionately large role in biologics spending, according to a statement released by the company.&nbsp;The company said that Canada’s biologic drug sales totaled approximately $10 billion in 2020, accounting for roughly one-third of all pharmaceutical expenditures. Biosimilars, such as Niopeg, have gained more traction there in recent years, helped by provincial policies that encourage switching from branded biologics.The launch follows last month’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-unit-launches-generic-anticonvulsant-in-canada/chlayAARbC6">rollout of a generic version of Gabapentin</a>, a standard treatment for neuropathic pain and epilepsy, now available in 100 mg, 300 mg, and 400 mg doses, packaged in bottles of 500 capsules.Sunshine Biopharma states that it currently has 72 generic drugs on the Canadian market and plans to introduce more before the end of the year. It’s also pursuing drug candidates in areas such as liver cancer and treatments related to the coronavirus.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/SBFM">Sunshine Biopharma</a> was ‘extremely bullish’ amid a 6,200% jump in 24-hour message volume.One user noted that for the first time in a long while, Sunshine Biopharma was holding onto its gains following a news release, calling the chart setup strong and suggesting the stock could be gearing up for a multi-day run.<stembedurl>https://stocktwits.com/Tryitin/message/619793472</stembedurl>Another user pointed to the significance of the product launch into a $10 billion market and expressed confidence that the stock could see substantial upside in the coming days, even speculating about a potential move into double digits.<stembedurl>https://stocktwits.com/Tryitin/message/619760589</stembedurl>The stock has declined 42.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In

The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients.

Shares of Sunshine Biopharma Inc. (SBFM) were in the spotlight on Wednesday after the pharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/06/20250611_SBFM_Press-Release_Launches-Gabapentine-1.pdf">announced</a> that its Canadian unit, Nora Pharma, has launched a new generic prescription drug, Gabapentin.Gabapentin is an anticonvulsant medication used to treat neuropathic pain and epilepsy, as well as for the treatment of pain caused by various medical conditions by reducing excess excitation of the neural networks in the brain and spinal cord.Nora Pharma’s Gabapentin is available in strengths of 100 mg, 300 mg, and 400 mg and comes in bottles of 500 capsules.According to Sunshine Pharma, Canada represents approximately 1.2% of the global pharmaceutical market for Gabapentin, which was valued at $1.92 billion in 2024. It is projected to reach $3.07 billion, the company said.CEO Steve Slilaty said that the company is attempting to fortify its presence in Canada’s generic drugs market, valued at $9.4 billion. The market is forecasted to nearly double to $19.2 billion by 2032, he added.Sunshine Biopharma currently has 71 generic prescription drugs on the market in Canada, with over 12 additional drugs planned for launch in the remainder of 2025.On Stocktwits, retail sentiment around SBFM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_1_14_32_PM_png_31faf5b9e5.webp" alt="SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits" width="631" height="67"><figcaption>SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that short sellers will not risk shorting Sunshine owing to its significant institutional ownership, low float, and ‘HUGE potential.’<stembedurl>https://stocktwits.com/LH1975New/message/617532142</stembedurl><a href="https://stocktwits.com/symbol/SBFM">SBFM stock</a> is down by about 46% this year and has wiped out nearly three-quarters of its valuation over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/intelligent-bio-rises-on-partnership-with-smartox/chlaUpbRbCy">Intelligent Bio Rises On Partnership With Smartox To Expand US Market Presence: Retail Hopes The Stock To Hit $2.6</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion.

Sunshine Biopharma, Inc.'s stock rose over 3% on Monday, lifting retail investor sentiment, after the company said its Canadian subsidiary had launched a generic version of an oncology drug.Nora Pharma launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market, Sunshine said.&nbsp;The drug is indicated for advanced renal cell carcinoma, breast cancer in certain post-menopausal women, some neuroendocrine tumors and tuberous sclerosis-related brain tumors.&nbsp;Sunshine said Everolimus is available in 2.5 mg, 5 mg and 10 mg strengths in 30-tablet blister packs.The global Everolimus market is valued at $2.5 billion in 2023 and is projected to hit around $4.8 billion by 2032, the company said.&nbsp;The announcement sent message volume on Stocktwits about Sunshine Biopharma soaring over 14,700% in the 24 hours to late Monday, even as the stock slid over 1% in after-hours trading.Sentiment among retail traders flipped to ‘extremely bullish’ from ‘bearish’ a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SBFM_sentiment_and_message_volume_as_of_April_21_png_ee65768271.webp" alt="SBFM sentiment and message volume as of April 21.png" width="1318" height="316"><figcaption>SBFM sentiment and message volume as of April 21. | source: Stocktwits</figcaption></figure>One watcher took heart from Everolimus' sales projections and said it "is going to blow someday."<stembedurl>https://stocktwits.com/JdNews/message/612158515</stembedurl>Another user speculated that the company was soon going to form strategic partnerships.<stembedurl>https://stocktwits.com/contra7/message/612209836</stembedurl>Earlier this month, Sunshine reported new preclinical data for its K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma (HCC).&nbsp;Sunshine’s stock, which has a short interest of 6.6% according to Koyfin, has lost over half its value this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug

Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

Sunshine Biopharma Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

SBFM
Sunshine Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SBFM News

SBFMSunshine Biopharma Inc